Left ventricular hypertrophy - The problem and possible solutions

Journal of International Medical Research

Volumn 33, Issue SUPPL. 1, 2005, Pages

  Gosse, P ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Angiotensin II receptor blockers; Hypertension; Left ventricular hypertrophy; Left ventricular mass; Pathophysiology; Treatment

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG TOLERABILITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HEART WORK; HUMAN; HYPERTENSION; PREDICTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 25844479714     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/14732300050330s102     Document Type: Article

References (56)

1. Massie BM: Myocardial hypertrophy and cardiac failure: a complex interrelationship. Am J Med 1983; 75: 67-74.
2. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.
3. Kahan T: The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998; 16 (Suppl 7): S23-S29.
4. Tin LL, Beevers DG, Lip GY: Hypertension, left ventricular hypertrophy, and sudden death. Curr Cardiol Rep 2002; 4: 449-457.
5. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP: Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108: 7-13.
6. Levy D, Murabito JM, Anderson KM, Christiansen JC, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
7. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
8. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117: 831-836.
9. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F: Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.
10. Vasan RS, Larson MG, Levy D, Evans JC, Benjamin EJ: Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation. Circulation 1997; 96: 1863-1873.
11. Cipriano C, Gosse P, Bemurat L, Mas D, Lemetayer P, N'tela G, et al: Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001; 14: 524-529.
12. Jern S: Assessment of left ventricular hypertrophy in patients with essential hypertension. Blood Press Suppl 1997; 2: 16-23.
13. Turk J: ST-T segment changes in patients with essential hypertension. Cor Vasa 1982; 24: 415-421.
14. Levy D, Labib S, Anderson K, Christiansen J, Kannel W, Castelli W: Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990; 81: 815-820.
15. Shapiro EP: Evaluation of left ventricular hypertrophy by magnetic resonance imaging. Am J Card Imaging 1994; 8: 310-315.
16. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, et al: Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90: 29-34.
17. Gosse P, Jullien V, Jarnier P, Lemetayer P, Clementy J: Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? J Hum Hypertens 1999; 13: 505-509.
18. Gosse P, Dallocchio M: Left ventricular hypertrophy: epidemiological prognosis and associated critical factors. Eur Heart J 1993; 14 (Suppl D): 16-21.
19. Fustinoni O: Editorial comment - left ventricular hypertrophy: an unseemly risk factor for stroke? Stroke 2003; 34: 2385-2386.
20. Girerd X, Laurent S, Pannier B, Asmar R, Safar M: Arterial distensibility and left ventricular hypertrophy in patients with sustained essential hypertension. Am Heart J 1991; 122 (4 Pt 2): 1210-1214.
21. Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, Laragh JH: Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension 1987; 9 (2 Pt 2): 1153-1160.
22. Rowlands DB, Ireland MA, Glover DR, McLeay RA, Stallard TJ, Littler WAL: The relationship between ambulatory blood pressure and echocardiographically assessed left ventricular hypertrophy. Clin Sci (Lond) 1981; 61 (Suppl 7): 101s-103s.
23. Devereux RB, Pickering TG: Relationship between the level, pattern and variability of ambulatory blood pressure and target organ damage in hypertension. J Hypertens 1991; 9 (Suppl 8): S34-S38.
24. White WB, Dey HM, Schulman P: Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension. Am Heart J 1989; 118: 782-795.
25. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, et al: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536.
26. Gosse P, Ansoborlo P, Jullien V, Lemetayer P, Clementy J: Ambulatory blood pressure and left ventricular hypertrophy. Blood Press Monit 1997; 2: 70-74.
27. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-1470.
28. Staessen JA, Bieniaszewski L, O'Brien E, Gosse P, Hayashi H, Imai Y, et al: Nocturnal blood pressure fall on ambulatory monitoring in a large international database. Hypertension 1997; 29: 30-39.
29. Gosse P, Lasserre R, Minifie C, Lemetayer P, Clementy J: Blood pressure surge on rising. J Hypertens 2004; 22: 1113-1118.
30. Ikeda T, Yamamoto K, Okada J, Hyayashida M, Yamada C, Kasatani T, et al: Morning rise in blood pressure associates with hypertensive cardiovascular complications. J Hypertens 2002; 20 (Suppl 4): S150.
31. Matsuo K, Kosugi T, Kamiya H, Yoshii K, Okada J, Gomi T, et al: Morning rise in blood pressure is a risk factor for cardiovascular complications in treated hypertensive patients. J Hypertens 2002; 20 (Suppl 4): S314.
32. Mulcahy D: Circadian variation in cardiovascular events. Blood Press Monit 1998; 3: 29-34.
33. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406.
34. Cuspidi C, Macca G, Sampieri L, Fusi V, Severgnini B, Michev I, et al: Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens 2001; 19: 1539-1545.
35. Gosse P, Herpin D: Can regression of left ventricular hypertrophy be proposed as a substitute criterion in trials of morbidity/mortality in hypertension (in French)? Arch Mal Coeur Vaiss 2000; 93 (11 Suppl): 1435-1440.
36. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al: Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356.
37. Erhardt L: Endothelial dysfunction and cardiovascular disease: the promise of blocking the renin - angiotensin system. Int J Clin Pract 2003; 57: 211-218.
38. Bouzeghrane F, Thibault G: Is angiotensin II a proliferative factor of cardiac fibroblasts? Cardiovasc Res 2002; 53: 304-312.
39. Schlaich MP, Schobel HF, Langenfeld MR, Hilgers K, Schmieder RE: Inadequate suppression of angiotensin II modulates left ventricular structure in humans. Clin Nephrol 1998; 49: 153-159.
40. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE: Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000; 85: 1199-1206.
41. Klingbeil A, Schneider M, Martus P, Messerli F, Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46.
42. Agabiti-Rosei E, Ambrosioni E, Dal Palu C, Muiesan ML, Zanchetti A: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens 1995; 13: 1325-1334.
43. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Frohlich ED: Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect. Am J Hypertens 1988; 1 (3 Pt 3): 214S-216S.
44. Wachtell K, Dahlof B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, et al: Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 2002; 144: 1057-1064.
45. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392.
46. Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, et al: Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000; 35: 587-594.
47. McConnaughey MM, McConnaughey JS, Ingenito AJ: Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 1999; 39: 547-559.
48. Dahlof B: Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001; 14: 174-182.
49. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, et al: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300.
50. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al: Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-1864.
51. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, et al: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-1176.
52. Thurmann PA: Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. Cardiology 1999; 91 (Suppl 1): 3-7.
53. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456-1462.
54. Siragy HM: Angiotensin receptor blockers: how important is selectivity? Am J Hypertens 2002; 15: 1006-1014.
55. Gosse P, Dubourg O, Gueret P: Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. J Hypertens 2003; 21: 217-221.
56. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, et al: Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16: 895-899.